Issa H. Safety of pegylated interferon and ribavirin therapy for chronic hepatitis C in patients with sickle cell anemia. World J Hepatol 2010; 2(5): 180-184 [PMID: 21160993 DOI: 10.4254/wjh.v2.i5.180]
Corresponding Author of This Article
Hussain Issa, MD, Division of Gastroenterology, Department of Internal Medicine, King Fahad Specialist Hospital, Dammam, PO Box 4012, Sayhat 7312-32437, Saudi Arabia. hussain31911@yahoo.com
Article-Type of This Article
Brief Articles
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/